Share Name Share Symbol Market Type Share ISIN Share Description
Ondine Biomed LSE:OBP London Ordinary Share CA68234M1068 COM SHS NPV
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 18.50p 0.00p 0.00p - - - 0.00 05:00:10
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -2.1 -25.7 - 23.46

Ondine Biomed Share Discussion Threads

Showing 1 to 6 of 25 messages
Chat Pages: 1
DateSubjectAuthorDiscuss
18/3/2010
16:45
There is a film called Ondine out now. This is why the share has gone up
volsung
19/11/2007
12:40
Ondine Biopharma Cor Ondine Bio preclinical tests show photodisinfection effective vs hospital bug LONDON (Thomson Financial) - Ondine Biopharma Corporation said its photodisinfection technology has shown a high level of effectiveness in preclinical trials against Pseudomonas aeruginosa, one of the most dangerous hospital-acquired pathogens. Ondine says the work provides important preclinical support for its photodisinfection programs for skin wounds, burns and outer ear infections. Nicolas Loebel, chief technology officer, said: "Pseudomonas is extremely difficult to kill and occurs throughout hospital environments as an opportunistic pathogen. Our photodisinfection system has demonstrated 100 pct eradication of Pseudomonas aeruginosa in planktonic (free-floating) cultures, and in excess of 99.9 pct kills in biofilms. "The data from the preclinical research supports our belief that our photodisinfection technology could provide significant benefits over conventional antipseudomonal therapies such as topical antibiotics or micronized silver," he said. "After launching Periowave, our ground-breaking photodisinfection treatment for adult periodontal disease, our new product development efforts are being focused into nasal MRSA decolonization, disinfection of skin wounds and burns and treatment of external ear infections. The combination of wide therapeutic window, absence of resistance and treatment speed implies a potentially new paradigm in the treatment of these complex infections," he said. ben.deighton@thomson.com bsd/cmr
waldron
09/10/2007
11:31
University College London and Ondine Biopharma Announce Breakthrough Staphyloccocal Photodisinfection Technology http://www.investegate.co.uk/Article.aspx?id=20071009120000P13E9
tlee05
23/8/2005
14:46
Just for info' http://biz.yahoo.com/prnews/050823/sftu012.html?.v=22 dan
_dan_
06/8/2004
14:53
Price at start of thread 84.5p
lo1980
06/8/2004
14:52
Ondine Biopharma Corporation (OBC) is a biopharmaceutical company focused on the commercial development of a laser-activated, non-antibiotic treatment for intraoral bacterial infections. OBC maintains corporate offices in Vancouver, Canada and Redmond Washington. The antibacterial technology was developed and patented by the Eastman Dental Institute, University College London (UCL). OBC acquired patent rights in 1999 and intends to complete both EU and US clinical trials prior to introduction of the product to periodontists and general dentists. OBC's has access to world-class microbiology facilities and expertise at three major Universities for development of further indications and expansion of the product pipeline.
lo1980
Chat Pages: 1
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:32 V: D:20161206 18:00:06